In a breakthrough for India’s pharmaceutical sector, firms including Hetero, Cipla, Annora, and Natco have won Chinese government bids to supply generic drugs like Dapagliflozin and Olaparib, marking a significant entry into China’s tightly controlled healthcare market

Beijing: Indian pharma firms operating in China have made some headway into the Chinese market winning bids to supply bulk generic drugs , specially the widely prescribed Dapagliflozin which is used to treat diabetes.

Indian firms, including Hyderabad-based Hetero Labs Limited , Natco Pharma, Cipla Ltd and Annora Pharma Private Limited, won the bids conducted by the Chinese health ministry for procurement of pharmaceuticals for its hospitals, according to the India-China Economic and Cultural Council (ICEC).

Hetero D

See Full Page